BioSpace News Archive

BIO-Europe Spring 2021 Kempen Life Sciences Conference 4 th SACHS Annual Neuroscience Innovation Forum 2021

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, March 25, 2021, after market close.

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the fourth quarter and full year ending December 31, 2020 on Thursday, March 25, 2021 after the U.S. financial markets close.

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data , Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approv al of EB613 IND for the Treatment of O steoporosis Enables Initial U.S. Clinical Trial ‒ ‒ Amgen Collaboration Continues to Progress ; Company Evaluating Additional Molecules, Including GLP-2, in Multiple Pre-clinical Studies ‒ ‒

Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug conjugate (ADC) candidates and a license to Pfizer’s ADC technology platform, enabling expansion of its ADC portfolio and further strengthening its developmental capabilities.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the appointment of Dr. Douglas D. Lind to its board of directors.

CARISMA Therapeutics Inc. , a clinical stage biopharmaceutical company spun out of the University of Pennsylvania ( Penn ) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed

Celebrities, radio personalities and a nationwide community of urban, R&B and gospel music fans raised $1.5 million during the 13th annual Urban Radio Cares for St. Jude Kids fundraising broadcast on March 11-12 to support patients battling cancer and other life-threatening diseases at St. Jude Children’s Research Hospital®.

– Dr. Kasibhatla brings deep drug development expertise across multiple mechanisms of action and therapeutic modalities, as well as a strong foundational understanding of tumor-intrinsic and immuno-oncology targets, to Boundless Bio –

Halberd Corporation filed an International Patent Cooperation Treaty application for coverage of the invention titled, “Method for Treating and Curing Covid-19 Infection.” The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous countries simultaneously.